Financial Contrast: OSR (NASDAQ:OSRH) versus Nuvation Bio (NYSE:NUVB)

OSR (NASDAQ:OSRH) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares OSR and Nuvation Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81 million	3.88	-$27.06 million	($0.37)	-0.54
Nuvation Bio	$62.90 million	26.54	-$204.63 million	($0.44)	-10.81

OSR has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for OSR and Nuvation Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
Nuvation Bio	1	2	9	0	2.67

Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 178.07%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than OSR.

Risk & Volatility

OSR has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

Profitability

This table compares OSR and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Insider and Institutional Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 36.9% of OSR shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nuvation Bio beats OSR on 8 of the 14 factors compared between the two stocks.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.